| Titre : |
Use of varenicline versus bupropion and risk of psychiatric adverse events |
| Type de document : |
texte imprimé |
| Auteurs : |
Björn Pasternak, Auteur ; Henrik Svanström, Auteur ; Anders Hviid, Auteur |
| Année de publication : |
2013 |
| Importance : |
8 p. |
| Langues : |
Anglais (eng) |
| Catégories : |
[DIVERS] discipline médicale, paramédicale et scientifique:médecine:médecine spécialisée:psychiatrie
[TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
|
| Index. décimale : |
TA 6.2.3.2 Autres produits |
| Résumé : |
Abstract
AIM:
To investigate whether varenicline use was associated with increased risk of psychiatric adverse events, compared with bupropion, another drug used for smoking cessation.
DESIGN, SETTING AND PARTICIPANTS:
We conducted a registry-based cohort study in Denmark, 2007-10, comparing new users of varenicline and bupropion in unmatched and 1 : 1 propensity score-matched analyses.
MEASUREMENTS:
Using Cox regression, we estimated the hazard ratio (HR) of any psychiatric adverse event (emergency department visit or in-patient admission with a psychiatric diagnosis) within 30 days following treatment initiation. The unmatched and matched analyses correspond to conventional crude and fully adjusted analyses, respectively.
FINDINGS:
In unmatched analyses, there were 106 (0.18%) psychiatric adverse events among 59 790 varenicline users (rate 22 events per 1000 person-years), compared with 46 (0.26%) events among 17 936 bupropion users (rate 31 per 1000); the HR was 0.69 [95% confidence interval (CI): 0.49-0.98]. In propensity score-matched analyses, 39 (0.22%) events occurred among 17 935 varenicline users (rate 27 per 1000), compared with 46 (0.26%) events among 17 935 bupropion users (rate 31 per 1000); varenicline was not associated with increased risk of psychiatric adverse events (HR 0.85, 95% CI: 0.55-1.30). The overall rate of psychiatric adverse events was substantially higher among participants with a history of psychiatric disorder than in patients without such history; the risk associated with varenicline did not differ significantly by history of psychiatric disorder.
CONCLUSIONS:
In Denmark, the risk of psychiatric adverse events diagnosed during an emergency department visit or in-patient admission was not significantly higher with varenicline use compared with bupropion. |
| Permalink : |
https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8040 |
|
Use of varenicline versus bupropion and risk of psychiatric adverse events (2013)
